KEY DETAILS
Ladbible reports that a 63-year-old retired truck driver from Maryland is legally blind after being prescribed Ozempic for diabetes in 2023.
Foreign Policy Journal reports that a government-funded study found the GLP-1 drug semaglutide extended lifespan in older, healthy mice by tempering the detrimental effects of aging.
University of California reports that a new study found semaglutide slowed the pace of biological aging by 9% in adults with HIV, as measured by the DunedinPACE epigenetic clock.
The South African reports that retatrutide, an experimental obesity drug still in clinical trials, is being sold openly in South Africa by social media influencers, gym instructors and hairdressers, according to Nicolaou.
Insider Monkey reports that Eli Lilly's stock returned 36.37% over the six months ending October 15.
Novo Nordisk is being sued by the Engel family, and Ladbible reports that a 63-year-old retired truck driver from Maryland is legally blind after being prescribed Ozempic for diabetes in 2023. Insider Monkey reports that Eli Lilly's stock returned 36.37% over the six months ending October 15. And the University of California reports that a new study found semaglutide slowed the pace of biological aging by 9% in adults with HIV.
Ladbible reports that the Maryland man, a 63-year-old retired truck driver, is now legally blind after being prescribed Ozempic for his diabetes in 2023. The outlet reports that he sought testing at The John Hopkins Wilmer Eye Institute and was subsequently diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), otherwise known as an eye stroke. Ladbible also reports that the Engel family is now suing Novo Nordisk, alleging the company did not warn patients and doctors about potential health risks connected to Ozempic. That lawsuit is an allegation, and Ladbible's report does not describe any court ruling on it.
A different kind of story looks at aging in a laboratory setting. Foreign Policy Journal reports, in an article published October 18, that a government-funded study found the GLP-1 drug semaglutide extended lifespan in older, healthy mice by tempering the detrimental effects of aging. The outlet cites the NIH press release, which says that compared with a control group, mice treated with the drug showed improved muscle and cognitive function. These are animal results, not findings about people.
A separate study turned to people rather than animals. The University of California, in a post published October 17, reports that a new study provides the first randomized, placebo-controlled clinical evidence that semaglutide slows the accumulation of biological aging markers in the DNA of adults with HIV. The university reports that the drug slowed the pace of biological aging by 9%, as measured by the DunedinPACE epigenetic clock. According to the University of California, participants treated with semaglutide showed a broad pattern of slower biological aging across epigenetic clocks linked to inflammation and blood, brain, heart, kidney, liver and metabolic health.
Not every GLP-1 story is about a lab or a courtroom. The South African reported on October 16 that drugmakers are urging law enforcement to crack down on illegal weight-loss drugs being sold in South Africa. The outlet reports that Nicolaou singled out retatrutide, an experimental obesity drug still in clinical trials, and said it is being sold openly in South Africa by social media influencers, gym instructors and hairdressers. According to The South African, the warning came as industry leaders, regulators and law enforcement met at a multi-stakeholder roundtable on counterfeit medicines in Pretoria on Wednesday, October 14.
On the business side, Insider Monkey reports that Eli Lilly's stock returned 36.37% over the six months ending October 15. The outlet reports that Mounjaro and Zepbound continue to drive most of Lilly's growth, while the company is also looking to expand its reach with oral drugs, international markets and treatments beyond obesity. Insider Monkey also reports that Eli Lilly is investing an additional $4.5 billion in its Indiana facilities, and that the number of hedge funds holding the stock increased to 152 from 132 in Q1.
You can find the full details on the Ozempic lawsuit at Ladbible, the mice aging study at Foreign Policy Journal, and the HIV study at the University of California's site. The South African has more on the retatrutide concerns in South Africa, and Insider Monkey has more on Eli Lilly's stock performance.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.